Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Invest New Drugs
2006 Sep 01;245:367-75. doi: 10.1007/s10637-005-5707-6.
Show Gene links
Show Anatomy links
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Acharya MR
,
Karp JE
,
Sausville EA
,
Hwang K
,
Ryan Q
,
Gojo I
,
Venitz J
,
Figg WD
,
Sparreboom A
.
???displayArticle.abstract???
AIMS: To evaluate elimination pathways of the histone deacetylase inhibitor MS-275 in vitro and screen for relationships between demographic factors that may affect its pharmacokinetics in vivo.
PATIENTS AND METHODS: Substrate specificity of MS-275 for the liver-specific organic anion transporting polypeptides (OATPs) was assessed using Xenopus laevis oocytes, and in vitro metabolism was evaluated using human liver microsomes. In vivo pharmacokinetic data were obtained from 64 adult patients (36 male/28 female; median age, 57 years) receiving MS-275 orally (dose range, 2 to 12 mg/m2).
RESULTS: Accumulation of [G-3H]MS-275 by oocytes expressing OATP1B1 or OATP1B3 was not significantly different from water-injected controls (p = 0.82). Furthermore, no metabolites could be detected after incubation of MS-275 in human liver microsomes, suggesting that hepatic metabolism is a minor pathway of elimination. The mean (+/- SD) apparent oral clearance of MS-275 was 38.5 +/- 18.7 L/h, with a coefficient of variation (%CV) of 48.7%. When clearance was adjusted for body-surface area (BSA), the inter-individual variability was similar (%CV = 50.1%). In addition, in a linear-regression analysis, except for adjusted ideal body weight (p = 0.02, |r| = 0.29), none of the studied measures (BSA, lean-body mass, ideal body weight, body-mass index, height, weight, age, and sex) was a significant covariate (p > 0.13; |r| < 0.11) for oral clearance.
CONCLUSIONS: The current analysis has eliminated a number of candidate covariates from further consideration as important determinants of MS-275 absorption and disposition. Furthermore, MS-275 can be added to the list of cancer drugs where BSA-based dosing is not more accurate than fixed dosing.
Acharya,
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
2006, Pubmed
Acharya,
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
2006,
Pubmed
Baker,
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
2002,
Pubmed
Bruno,
Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel.
2001,
Pubmed
Cosolo,
Lean body mass, body surface area and epirubicin kinetics.
1994,
Pubmed
Dobbs,
What is the effect of adjusting epirubicin doses for body surface area?
1998,
Pubmed
Du Bois,
A formula to estimate the approximate surface area if height and weight be known. 1916.
1989,
Pubmed
Egorin,
Overview of recent topics in clinical pharmacology of anticancer agents.
1998,
Pubmed
Felici,
Dosing strategies for anticancer drugs: the good, the bad and body-surface area.
2002,
Pubmed
Gibbs,
The impact of obesity and disease on busulfan oral clearance in adults.
1999,
Pubmed
Grochow,
Is dose normalization to weight or body surface area useful in adults?
1990,
Pubmed
Gurney,
How to calculate the dose of chemotherapy.
2002,
Pubmed
Gurney,
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996,
Pubmed
Gurney,
Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
1998,
Pubmed
Hwang,
Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.
2004,
Pubmed
Jaboin,
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
2002,
Pubmed
Karanam,
In vitro metabolism of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl) phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor alpha/gamma agonist. I. Role of cytochrome P450, methyltransferases, flavin monooxygenases, and esterases.
2004,
Pubmed
Kouraklis,
Histone deacetylase inhibitors and anticancer therapy.
2002,
Pubmed
Lee,
MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
2001,
Pubmed
Lucas,
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.
2004,
Pubmed
Marks,
Histone deacetylases and cancer: causes and therapies.
2001,
Pubmed
Marzolini,
Pharmacogenomics of the OATP and OAT families.
2004,
Pubmed
Morgan,
Lean body mass as a predictor of drug dosage. Implications for drug therapy.
1994,
Pubmed
Mosteller,
Simplified calculation of body-surface area.
1987,
Pubmed
Ratain,
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?
1998,
Pubmed
Rosato,
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
2003,
Pubmed
Rudek,
Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies.
2003,
Pubmed
Saito,
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
1999,
Pubmed
Sawyer,
Body surface area as a determinant of pharmacokinetics and drug dosing.
2001,
Pubmed
Shitara,
Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs.
2005,
Pubmed
Suzuki,
Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.
1999,
Pubmed
de Jongh,
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
2001,
Pubmed